Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial

The Lancet 2026

View at publisher
Authors: Harpreet S. Bajaj, Michelle Welch, Parag Shah, Eduardo Luna, Fatima-Zahra Jaouimaa, Bing Liu, Rong Liu, Yanyun Chen, Hiren Patel, Amy Bartee
DOI: 10.1016/s0140-6736(26)00967-0
Cited by: 11
References: 26

Fields of Study & Subjects

Diabetes Treatment and Management Bariatric Surgery and Outcomes Metabolism Diabetes and Cancer

Publication details

Journal / source
The Lancet
Publisher
Elsevier BV
Volume
407
Issue
10546
Pages
2402–2413
Publication date
1 June 2026
Language
EN